Stockscreener 앱 받기
80.09
2.50%
-2.05
전일 마감가:
$82.14
열려 있는:
$82.38
하루 거래량:
1.82M
Relative Volume:
7.39
시가총액:
$15.69B
수익:
$579.96M
순이익/손실:
$-729.89M
주가수익비율:
-21.38
EPS:
-3.7459
순현금흐름:
$-452.02M
1주 성능:
-4.68%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$79.45
$82.40
1주일 범위
$79.45
$86.32
52주 변동 폭
$78.98
$86.32
Bio Rad Laboratories Inc Stock (BBIO) Company Profile
명칭
Bio Rad Laboratories Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO
Compare BBIO vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bio Rad Laboratories Inc
|
80.09 | 16.48B | 579.96M | -729.89M | -452.02M | -3.7459 |
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc 주식(BBIO)의 최신 뉴스
BIO|Bio Rad Laboratories Inc|Price:316.410|Chg%:+1.950 - TradingKey
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bio Rad Laboratories Inc (BIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio Rad Laboratories Inc (BIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BIO|Bio Rad Laboratories Inc|Price:314.460|Chg%:-1.760 - TradingKey
TradingKey - TradingKey
Bio-Rad Laboratories (BIO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Insight Molecular Diagnostics Ord Shs (IMDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bio-Rad Laboratories, Inc. (BIO) Stock forecasts - Yahoo Finance Singapore
Bio-Rad Laboratories (BIO) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Bio-Rad Laboratories Inc (BIO) Stock Up 3.4% and Still Undervalued -- GF Score: 72/100 - GuruFocus
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026 - BioSpace
Press Release: Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Moomoo
Bio-Rad will discuss Q2 results at 5 p.m. ET on Aug. 4 - Stock Titan
Bio-Rad to report Q2 2026 results, host conference call - Bitget
Bio-Rad Laboratories stock holds on to year-end earnings context - Ad-hoc-news.de
Bio-Rad Laboratories (BIO) Experiences Minor Decline Amid Compet - GuruFocus
Bio Rad Laboratories (BIO) Stock Looks Fairly Valued After A 57% Slide - Sahm
Bio-Rad Q1 2026 Earnings: EPS Misses Estimates by 5.68%, Stock Edges Higher on Resilient Business TrendsRevenue Breakdown Analysis - po-news-eg.net
Diagnostic Reagent Market is Going to Boom: New Report Reveals - openPR.com
(BIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
ETFs Investing in Bio-Rad Laboratories, Inc. Class A Stocks - TradingView
BIO5368763 Bond Coupon Profile — Rate & Payments - TradingView
BIO5368763 Bond Risk Profile - TradingView
BIO5368763 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Coupon Profile — Rate & Payments - TradingView
Bio-Rad unveils Vericheck ddPCR kits for QX700 QC - Select Science
Price to earnings forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate - Sahm
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 4.7% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad launches Vericheck ddPCR Kits compatible with QX700 platform for biopharma quality control and cell and gene therapy workflows - News-Medical
Bio-Rad Releases New Quality Control Kits for Cell and Gene Therapy - Clinical Lab Products
IVD Quality Control Market Size, Share | Industry Report [2034] - Fortune Business Insights
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential (NYSE:BIO) - Seeking Alpha
BIO Forecast — Price Target — Prediction for 2027 - TradingView
Price-Driven Insight from (BIO) for Rule-Based Strategy - Stock Traders Daily
2x Valuation Gap: BIO vs. CRL — Who’s Wrong? - NAI500
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - Yahoo Finance
In Fight With GC, Bio-Rad Adds Quinn Emanuel to Legal Team - Law.com
Bio-Rad Receives MicroVal Validation for Two EZ-Check Listeria Testing Kits - Quality Assurance & Food Safety
Bio-Rad receives microVal validation for EZ-CheckTM Listeria spp. and EZ-Check Listeria monocytogenes Testing Kits - Cambridge Network
Bio-Rad Laboratories (BIO) Surges 4.4% as Bullish Momentum Builds From Key Support LevelOBV Divergence - dars.gov.et
Is Elliott’s Sartorius Push Altering The Investment Case For Bio-Rad Laboratories (BIO)? - Yahoo Finance
Elliott Targets Bio-Rad After 70% Stock Collapse - Yahoo Finance
Elliott Stake Puts Bio-Rad Turnaround Plans And Sartorius Holding In Focus - Sahm
Elliott builds big stake in life-science firm Bio-Rad Labs, WSJ reports - MSN
Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday - Benzinga
Elliott Management Takes Stake in Bio-Rad to Boost Stock Performance (BIO) - GuruFocus
Bio Rad Laboratories Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bio Rad Laboratories Inc 주식 (BBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ellis Andrea | Director |
Jul 09 '26 |
Sale |
84.00 |
17,167 |
1,442,028 |
22,579 |
| Cook Jennifer E. | Director |
Jul 09 '26 |
Option Exercise |
24.96 |
148,589 |
3,708,335 |
156,972 |
| Cook Jennifer E. | Director |
Jul 09 '26 |
Sale |
88.54 |
148,589 |
13,156,008 |
8,383 |
1.04%
11.95%
자본화:
|
볼륨(24시간):